Anti-Human TNF alpha (Adalimumab) – Dylight 488®

Home/Recombinant Antibodies/Biosimilar Recombinant Antibodies/Anti-Human TNF alpha (Adalimumab) – Dylight 488®

Pricing & Details

Product No.LT111
Clone
D2E7
Protein
TNF alpha
Formats AvailableView All
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
DIF; TNFA; TNFSF2; TNLG1F; TNF-alpha
Isotype
Human IgG1κ
Applications
FA
,
FC
,
IF
,
IHC
Prod No.
Size
Price
Avail.
Qty
Add to cart
LT111-100 μg
100 µg
$325.00
Made to Order
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Human
Expression Host
HEK-293
FC Effector Activity
Active
Immunogen
Human TNF alpha
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
Next Day 2-8°C
Excitation Laser
Blue Laser (493 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
FA
IF
IHC
Additional Reported Applications For Relevant Conjugates ?
B
N
IP
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Adalimumab. Clone D2E7 binds to soluble TNF- α, but not to TNF- β (lymphotoxin). This product is for research use only.
Antigen Distribution
TNF-α is secreted by macrophages, monocytes, neutrophils, T cells, B cells, NK cells, LAK cells.
Background
Adalimumab is a research-grade monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNF-α). TNF-α is a 17.5 kD protein that mediates inflammation and immunity caused by the invasion of viruses, bacteria, and parasites by initiating a cascade of cytokines that increase vascular permeability, thus bringing macrophages and neutrophils to the site of infection. TNF-α secreted by the macrophage causes the blood to clot which provides containment of the infection. TNF-α inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis, and juvenile idiopathic arthritis. Adalimumab blocks the interaction with the p55 and p75 cell surface TNF receptors thus, neutralizing the biological function of TNF. Anti-Human TNF alpha (Adalimumab) utilizes the same variable regions from the therapeutic antibody Adalimumab making it ideal for research projects.

Antigen Details

Protein
PubMed
NCBI Gene Bank ID

References & Citations

1. Omidinia, E. et al. (2019) Protein Expr Purif. 155:59-65.
Flow Cytometry
IHC

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok